[AMRN] Amarin Corporation plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.11 Change: 0.12 (4.01%)
Ext. hours: Change: 0 (0%)

chart AMRN

Refresh chart

Strongest Trends Summary For AMRN

AMRN is in the medium-term down -33% below S&P in 2 months. In the long-term up 305% in 2 years and up 621% in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Fundamental Ratios
Shares Outstanding EPS-0.33 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 26.39% Sales Growth - Q/Q-3.32% P/E-8.88
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.56% ROE99.49% ROI-38.89%
Current Ratio4.46 Quick Ratio4.08 Long Term Debt/Equity1.49 Debt Ratio-0.69
Gross Margin63.04% Operating Margin-164.67% Net Profit Margin-103.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities54.3 M Cash From Investing Activities Cash From Operating Activities-12.64 M Gross Profit10.31 M
Net Profit-31.13 M Operating Profit-27.05 M Total Assets215.34 M Total Current Assets189.75 M
Total Current Liabilities42.53 M Total Debt233.48 M Total Liabilities277.16 M Total Revenue15.93 M
Technical Data
High 52 week23.16 Low 52 week2.45 Last close14.77 Last change-17.07%
RSI28.68 Average true range1.05 Beta0.52 Volume2.65 M
Simple moving average 20 days-19.43% Simple moving average 50 days-22.43% Simple moving average 200 days-19.41%
Performance Data
Performance Week-14.38% Performance Month-34.36% Performance Quart-14.67% Performance Half-12.14%
Performance Year418.25% Performance Year-to-date8.52% Volatility daily4.91% Volatility weekly10.97%
Volatility monthly22.49% Volatility yearly77.91% Relative Volume527.59% Average Volume8.48 M
New High New Low

News

2019-09-09 10:35:00 | Amarin: Keep Your Dry Powder Ready

2019-09-05 10:12:29 | 3 “Strong Buy” Biotech Stocks Ahead of FDA Verdicts

2019-09-03 06:00:00 | New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Management of Dyslipidaemias Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study

2019-08-28 06:00:00 | Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference

2019-08-27 11:43:10 | Does Amarin NASDAQ:AMRN Have A Healthy Balance Sheet?

2019-08-27 06:00:00 | Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management

2019-08-26 04:11:28 | Why ‘Strong Buy’ Amarin Can Double, Say Top Analysts

2019-08-22 13:31:00 | 3 Top Healthcare Stocks to Buy Right Now

2019-08-21 06:00:00 | Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference

2019-08-20 13:06:30 | 8 Biotech Stocks to Watch After the Q2 Earnings Season

2019-08-18 07:37:17 | 3 Healthcare Stocks to Fight Off the Market Flu

2019-08-17 11:04:00 | Better Buy: GW Pharmaceuticals vs. Amarin

2019-08-15 12:27:27 | Another Day, Another Buy Rating for Amarin AMRN Stock

2019-08-14 11:31:00 | Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout

2019-08-14 09:21:01 | Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

2019-08-12 18:05:38 | Don’t Say Bye Bye to Amarin AMRN Stock, Say Buy Buy

2019-08-09 15:49:29 | Amarin Stock Crashes as FDA Plans Panel Review

2019-08-09 15:13:58 | Pharma companies Amarin, Nektar Therapeutics nosedive on product concerns

2019-08-09 15:04:27 | How the 10 Best Stocks From Last Year Hold Up Today

2019-08-09 13:50:00 | Why Amarin Stock Is Tanking Today

2019-08-09 13:33:48 | Drugmakers Put Bad Spin on a Bizarre Week

2019-08-09 11:39:56 | Biotech Investors Jolted Out of Summer Lull as High-Fliers Sink

2019-08-09 10:52:21 | Amarin Shares Topple On Adcom Meeting Surprise For Fish Oil Pill

2019-08-09 08:53:00 | Amarin AMRN Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm

2019-08-09 07:19:03 | The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

2019-08-09 06:49:00 | [video]Amarin Dives on Surprise FDA Heart-Drug Review

2019-08-08 16:30:00 | Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA

2019-08-06 15:40:06 | Biotech Stocks to Watch Through the 2nd Half of 2019

2019-08-02 06:41:38 | Edited Transcript of AMRN earnings conference call or presentation 31-Jul-19 11:30am GMT

2019-08-01 17:06:57 | Amarin’s Q2 Earnings and Robust 2019 Outlook

2019-07-31 15:00:00 | What You'll Want to Know About Amarin's Strong Q2 Results

2019-07-31 13:23:40 | Amarin Corporation plc AMRN Q2 2019 Earnings Call Transcript

2019-07-31 10:30:00 | 3 Takeaways From Amarin's Earnings

2019-07-31 07:56:11 | Amarin AMRN Beats Earnings & Beats Revenues in Q2

2019-07-31 07:06:00 | The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

2019-07-31 05:00:00 | Amarin Reports Second Quarter 2019 Financial Results and Operational Update

2019-07-30 14:13:40 | A Preview Of Amarin's Q2 Earnings

2019-07-26 11:50:03 | What's in the Cards for Amarin AMRN This Earnings Season?

2019-07-24 11:18:31 | Amarin Is Just Running Up That Hill; Peak Sales Could Reach $10B, Says Analyst

2019-07-24 06:00:00 | Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019

2019-07-21 13:53:00 | Amarin: Is a Buyout Really Off the Table?

2019-07-20 08:00:06 | IBD Stock Of The Day: Winners, Losers — And This FANG Stock 22

2019-07-19 12:39:45 | A Look At Benzinga Pro's Most-Searched Tickers For July 19, 2019

2019-07-18 23:47:19 | Amarin Prices Public Offering of American Depositary Shares

2019-07-18 16:33:00 | Why United Rentals, Eagle Bancorp, and Amarin Slumped Today

2019-07-18 13:47:00 | Here's Why Amarin Stock Tumbled Today

2019-07-17 16:01:00 | Amarin Announces $400,000,000 Public Offering of American Depositary Shares

2019-07-15 10:17:00 | 2 Incredibly Cheap Biotech Stocks to Buy Now

2019-07-12 16:36:12 | Soaring Amarin Stock Netted Quick Swing Trading Profit

2019-07-11 13:07:05 | Amarin NASDAQ:AMRN Shareholders Have Enjoyed A Magnificent 1356% Share Price Gain